PFE vs. JNJ, MRK, ABBV, BMY, ZTS, RPRX, JAZZ, PRGO, CORT, and SUPN
Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.
Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk.
In the previous week, Johnson & Johnson had 2 more articles in the media than Pfizer. MarketBeat recorded 38 mentions for Johnson & Johnson and 36 mentions for Pfizer. Pfizer's average media sentiment score of 0.70 beat Johnson & Johnson's score of 0.52 indicating that Pfizer is being referred to more favorably in the media.
Pfizer has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.
Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 5.9%. Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.4%. Pfizer pays out -2,799.5% of its earnings in the form of a dividend. Johnson & Johnson pays out 30.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.
Johnson & Johnson has higher revenue and earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.
Johnson & Johnson has a net margin of 45.26% compared to Pfizer's net margin of -0.56%. Johnson & Johnson's return on equity of 36.70% beat Pfizer's return on equity.
Pfizer currently has a consensus price target of $35.86, suggesting a potential upside of 25.11%. Johnson & Johnson has a consensus price target of $174.07, suggesting a potential upside of 18.68%. Given Pfizer's stronger consensus rating and higher possible upside, equities research analysts clearly believe Pfizer is more favorable than Johnson & Johnson.
Pfizer received 404 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 69.06% of users gave Pfizer an outperform vote while only 64.93% of users gave Johnson & Johnson an outperform vote.
68.4% of Pfizer shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Johnson & Johnson beats Pfizer on 11 of the 20 factors compared between the two stocks.
Get Pfizer News Delivered to You Automatically
Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
